High prevalence of the metabolic syndrome in HIV-infected patients: Impact of different definitions of the metabolic syndrome

AIDS

Volumn 24, Issue 3, 2010, Pages 427-435

  Worm, Signe W ^a   Friis Møller, Nina ^a   Bruyand, Mathias ^d   Monforte, Antonella D'Arminio ^e   Rickenbach, Martin ^f   Reiss, Peter ^c   El Sadr, Wafaa ^g   Phillips, Andrew ^b   Lundgren, Jens ^a   Sabin, Caroline ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c STICHTING HIV MONITORING   (Netherlands)

^d INSERM   (France)

^e UNIVERSITY OF MILAN   (Italy)

^f LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^g Harlem Hospital ^*  (United States)

Author keywords

Epidemiology; HIV; Metabolic syndrome; Observational study

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PREVALENCE; PRIORITY JOURNAL;

ADULT; ANTIHYPERTENSIVE AGENTS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; HYPOLIPIDEMIC AGENTS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PREVALENCE; PROSPECTIVE STUDIES; UNITED STATES;

EID: 75649129691     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328334344e     Document Type: Article

References (25)

1. Expert panel on detection EaToHBCiA. Executive summary of the third report of the national cholesterol educational program (NCEP) expert panel on detection, evaluation and treatment of high cholesterol in adults (Adult treatment III). JAMA 2005; 285:2486-2497.
2. Fontas E, van LF, Sabin CA, Friis-Moller N, Rickenbach M, d'Arminio MA, et al. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? J Infect Dis 2004; 189:1056-1074.
3. Riddler SA, Smit E, Cole SR, Li R, Chmiel JS, Dobs A, et al. Impact of HIV infection and HAART on serum lipids in men. JAMA 2003; 289:2978-2982.
4. Young J, Weber R, Rickenbach M, Furrer H, Bernasconi E, Hirschel B, et al. Lipid profiles for antiretroviral-naive patients starting PI-and NNRTI-based therapy in the Swiss HIV cohort study. Antivir Ther 2005; 10:585-591. (Pubitemid 41224950)
5. Jacobson DL, Tang AM, Spiegelman D, Thomas AM, Skinner S, Gorbach SL, et al. Incidence of metabolic syndrome in a cohort of HIV-infected adults and prevalence relative to the US population (National Health and Nutrition Examination Survey). J Acquir Immune Defic Syndr 2006; 43:458-466.
6. Samaras K, Wand H, Law M, Emery S, Cooper D, Carr A. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia. Diabetes Care 2007; 30:113-119. (Pubitemid 46052508)
7. Bergersen BM, Schumacher A, Sandvik L, Bruun JN, Birkeland K. Important differences in components of the metabolic syndrome between HIV-patients with and without highly active antiretroviral therapy and healthy controls. Scand J Infect Dis 2006; 38:682-689.
8. Sobieszczyk ME, Hoover DR, Anastos K, Mulligan K, Tan T, Shi Q, et al. Prevalence and predictors of metabolic syndrome among HIV-infected and HIV-uninfected women in the Women's Interagency HIV Study. J Acquir Immune Defic Syndr 2008; 48:272-280.
9. Grinspoon SK. Metabolic syndrome and cardiovascular disease in patients with human immunodeficiency virus. Am J Med 2005; 118 (Suppl 2):23S-28S.
10. Jerico C, Knobel H, Montero M, Ordonez-Llanos J, Guelar A, Gimeno JL, et al. Metabolic syndrome among HIV-infected patients: prevalence, characteristics, and related factors. Diabetes Care 2005; 28:132-137.
11. Bonfanti P, Giannattasio C, Ricci E, Facchetti R, Rosella E, Franzetti M, et al. HIV and metabolic syndrome: a comparison with the general population. J Acquir Immune Defic Syndr 2007; 45:426-431.
12. Mondy K, Overton ET, Grubb J, Tong S, Seyfried W, Powderly W, et al. Metabolic syndrome in HIV-infected patients from an urban, midwestern US outpatient population. Clin Infect Dis 2007; 44:726-734.
13. Adeyemi O, Rezai K, Bahk M, Badri S, Thomas-Gossain N. Metabolic syndrome in older HIV-infected patients: data from the CORE50 cohort. AIDS Patient Care STDS 2008; 22:941-945.
14. Friis-Moller N, Sabin CA, Weber R, d'Arminio MA, El-Sadr WM, Reiss P, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349:1993-2003.
15. Friis-Moller N, Weber R, Reiss P, Thiebaut R, Kirk O, d'Arminio MA, et al. Cardiovascular disease risk factors in HIV patients: association with antiretroviral therapy. Results from the DAD study. AIDS 2003; 17:1179-1193.
16. Worm SW, Sabin CA, Reiss P, El-Sadr W, Monforte AD, Pradier C, et al. Presence of the metabolic syndrome (MS) is not a better predictor of cardiovascular disease (CVD) than the sum of its components in HIV-infected individuals. Data Collection on Adverse Events of Anti-HIV Drugs (The D:A:D study). Diabetes Care 2009; 32:474-480.
17. WandH, Calmy A, Carey DL, Samaras K, Carr A,Law MG, et al. Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. AIDS 2007; 21:2445-2453.
18. Sabin CA, Weber R, Fontas E, Dabis F, Wit SD, Worm SW, et al.; On behalf of the D:A:D Study Group. Underutilisation of recommended interventions for the prevention of coronary heart disease (CHD) in HIV-infected patients with established cardiovascular disease or diabetes mellitus: results from a multicohort study. 14th Conference on Retroviruses and Opportunistic Infections (CROI), Los Angeles, USA, 2007.
19. Grundy SM. Metabolic syndrome scientific statement by the American Heart Association and the National Heart, Lung, and Blood Institute. Arterioscler Thromb Vasc Biol 2005; 25:2243-2244.
20. Gotto AM Jr, Blackburn GL, Dailey GE III, Garber AJ, Grundy SM, Sobel BE, et al. The metabolic syndrome: a call to action. Coron Artery Dis 2006; 17:77-80.
21. Olijhoek JK, van der GY, Haffner SM, Visseren FL. Defining the metabolic syndrome: resolving unresolved issues? Eur J Intern Med 2007; 18:309-313.
22. Dube MP, Stein JH, Aberg JA, Fichtenbaum CJ, Gerber JG, Tashima KT, et al. Guidelines for the evaluation and management of dyslipidemiain human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 2003; 37:613-627.
23. Lundgren JD, Battegay M, Behrens G, De WS, Guaraldi G, Katlama C, et al. European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV. HIV Med 2008; 9:72-81.
24. Sattar N, McConnachie A, Shaper AG, Blauw GJ, Buckley BM, de Craen AJ, et al. Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. Lancet 2008; 371:1927-1935.
25. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal-joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005; 28:2289-2304. (Pubitemid 41242486)